Inhaled hope for cancer patients fighting dangerous viruses
Disease control
Recruiting now
This study is testing an experimental inhaled drug, PUL-042, to see if it can reduce the severity of lung infections caused by common respiratory viruses in a very vulnerable group. The participants are adults with blood cancers or who have received a stem cell transplant, and wh…
Phase: PHASE2 • Sponsor: Pulmotect, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC